Literature DB >> 14636354

Epilepsy and multiple sclerosis in Sicily: a population-based study.

Alessandra Nicoletti1, Vito Sofia, Roberto Biondi, Salvatore Lo Fermo, Ester Reggio, Francesco Patti, Arturo Reggio.   

Abstract

PURPOSE: To evaluate the association between epilepsy and multiple sclerosis (MS), we analyzed the incidence of epilepsy in a population-based incidence cohort of MS in Catania, Sicily.
METHODS: According to Poser's diagnostic criteria, 170 incident cases of MS have been identified from 1975 to 1994 in the city of Catania. All these subjects underwent a complete neurological examination to confirm the diagnosis of MS and to identify those patients with a history of seizures. Diagnosis of epilepsy was based on the criteria proposed by the International League Against Epilepsy (ILAE) in 1993, and seizures were classified according to the classification of the ILAE, 1981.
RESULTS: From 1975 to 1994, 170 subjects with MS had the clinical onset of the disease. The mean annual incidence of MS was 2.3/100,000 (95% CI, 2.0-2.6). Of the 170 defined MS patients, four developed epilepsy after the onset and also diagnosis of MS, giving an incidence rate of epilepsy of 285/100,000 person years at risk (95% CI, 119-684) and 147.8/100,000 when age adjusted to the world standard population. The cumulative risk of developing epilepsy after the onset of MS, evaluated by using the life-table methods, was zero at 1 year and 1.76% at 5 years. Of these four patients, three were classified as having partial seizures with secondary generalization and one with tonic-clonic seizures.
CONCLUSIONS: Our data are consistent with those reported in literature suggesting that the risk of developing epilepsy is threefold higher among MS patients than in the general population.

Entities:  

Mesh:

Year:  2003        PMID: 14636354     DOI: 10.1046/j.1528-1157.2003.09203.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  13 in total

Review 1.  Seizures in patients with multiple sclerosis: epidemiology, pathophysiology and management.

Authors:  Brendan J Kelley; Moses Rodriguez
Journal:  CNS Drugs       Date:  2009-10       Impact factor: 5.749

2.  Symptomatic therapy in multiple sclerosis: a review for a multimodal approach in clinical practice.

Authors:  João Carlos Correia de Sa; Laura Airas; Emmanuel Bartholome; Nikolaos Grigoriadis; Heinrich Mattle; Celia Oreja-Guevara; Jonathan O'Riordan; Finn Sellebjerg; Bruno Stankoff; Karl Vass; Agata Walczak; Heinz Wiendl; Bernd C Kieseier
Journal:  Ther Adv Neurol Disord       Date:  2011-05       Impact factor: 6.570

Review 3.  Risk factors for unprovoked epileptic seizures in multiple sclerosis: a systematic review and meta-analysis.

Authors:  Sara Gasparini; Edoardo Ferlazzo; Michele Ascoli; Chiara Sueri; Vittoria Cianci; Concetta Russo; Laura Rosa Pisani; Pasquale Striano; Maurizio Elia; Ettore Beghi; Carmela Colica; Umberto Aguglia
Journal:  Neurol Sci       Date:  2017-01-04       Impact factor: 3.307

Review 4.  Prevalence of Seizure/Epilepsy in Patients with Multiple Sclerosis: A Systematic Review and Meta-Analysis.

Authors:  Omid Mirmosayyeb; Vahid Shaygannejad; Nasim Nehzat; Aida Mohammadi; Mahsa Ghajarzadeh
Journal:  Int J Prev Med       Date:  2021-02-24

5.  Does early-onset multiple sclerosis differ from adult-onset form in Iranian people.

Authors:  Fereshteh Ashtari; Vahid Shaygannejad; Ziba Farajzadegan; Ali Amin
Journal:  J Res Med Sci       Date:  2010-03       Impact factor: 1.852

Review 6.  A systematic review of the incidence and prevalence of sleep disorders and seizure disorders in multiple sclerosis.

Authors:  Ruth Ann Marrie; Nadia Reider; Jeffrey Cohen; Maria Trojano; Per Soelberg Sorensen; Gary Cutter; Stephen Reingold; Olaf Stuve
Journal:  Mult Scler       Date:  2014-12-22       Impact factor: 6.312

Review 7.  A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: overview.

Authors:  Ruth Ann Marrie; Jeffrey Cohen; Olaf Stuve; Maria Trojano; Per Soelberg Sørensen; Stephen Reingold; Gary Cutter; Nadia Reider
Journal:  Mult Scler       Date:  2015-01-26       Impact factor: 6.312

8.  Dalfampridine extended release tablets: 1 year of postmarketing safety experience in the US.

Authors:  Michele Jara; Graham Barker; Herbert R Henney
Journal:  Neuropsychiatr Dis Treat       Date:  2013-03-10       Impact factor: 2.570

9.  Seizure characteristics in multiple sclerosis patients.

Authors:  Vahid Shaygannejad; Fereshteh Ashtari; Mohammad Zare; Majid Ghasemi; Rasul Norouzi; Helia Maghzi
Journal:  J Res Med Sci       Date:  2013-03       Impact factor: 1.852

10.  Seizure in Iranian patients with multiple sclerosis.

Authors:  Mohammad Zare; Rasul Norouzi; Vahid Shayegannejad; Fereshteh Ashtari; Majid Ghasemi; Hemaseh Tavahen; Ali Masaeli
Journal:  J Res Med Sci       Date:  2013-07       Impact factor: 1.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.